Managing patients with thrombotic vascular disease is complex and challenging:
- Ischemic vascular disease remains a complicated interplay of atherosclerosis and thrombosis even with the evolution in our understanding of the pathobiology of thrombosis.
- There has been tremendous growth in therapeutic options which are quickly finding their place in daily practice, including a remarkable expansion in the number of intravenous and oral antithrombotic agents and new antiplatelet agents
Now more than ever, all cardiologists, hematologists, and specialists in vascular medicine, as well as other professionals, such as hospital pharmacists, who deal with prognosis and intervention in preventing thrombosis, need a resource that distills current knowledge of this important subject.
Written and edited by today s leading international, Therapeutic Advances in Thrombosis, 2e provides physicians with the very latest in medical and surgical advances in antithrombotic therapies. With this comprehensively updated edition you get:
- Coverage of virtually all aspects of venous and arterial thrombotic disease and the corresponding therapies
- Strategies to manage specific clinical conditions and how to tailor treatment to individual patient needs
- Updated chapters covering thrombolysis in ST–elevated myocardial infarctions; thrombosis in patients with diabetes, pregnancy, and renal dysfunction
- Special emphasis on the pharmacology of novel anticoagulants and their practical use in venous thromboembolism and atrial fibrillation.
Plus, all chapters fully explore clinical trial designs and outcomes for particular treatment therapies, as well as contain the relevant ACC/AHA/ESC guidelines, so you can confidently apply what you learn.
1 Arterial thrombosis: a brief overview, 1Lina Badimon and Valentin Fuster
2 Aspirin, 12Carlo Patrono
3 Platelet ADP P2Y12 inhibitors: thienopyridines, 26Joseph D. Foley III and David J. Moliterno
4 Platelet ADP P2Y12 inhibitors: nonthienopyridines, 47Joseph D. Foley III and David J. Moliterno
5 Cilostazol and dipyridamole: more than weak inhibition of platelets, 62Wolfgang G. Eisert
6 Interrelationship of thrombin and platelets: the protease activated receptor–1, 71Matthew E. Wiisanen and David J. Moliterno
7 Glycoprotein IIb/IIIa inhibitors, 87Marco Valgimigli and Elisa Cangiano
8 Unfractionated heparin and low molecular weight heparin in ischemic heart disease, 111Zafar Iqbal, Omar Hasan, and Marc Cohen
9 Pentasaccharide derivatives, 128Antonio Gutierrez, Pierluigi Tricoci, and John H.P. Alexander
10 Intravenous direct thrombin inhibitors, 150Femi Philip and A. Michael Lincoff
11 Vitamin K antagonists, 166Freek W.A. Verheugt
12 Oral direct thrombin inhibitors and oral factor Xa inhibitors, 180Steen Husted and Lars Wallentin
13 Thrombolytic therapy and concomitant antithrombotic therapies, 189Peter R. Sinnaeve and Frans J. Van de Werf
14 Antithrombotic therapy in ST–segment elevation myocardial infarction, 205Kurt Huber, Raffaele De Caterina, and Steen Dalby Kristensen
15 Antithrombotic therapy in non ST–segment elevation acute coronary syndromes, 213Georgios J. Vlachojannis, Vijayalakshmi Kunadian, Joseph M. Sweeny, and Roxana Mehran
16 Antithrombotic strategies in patients undergoing elective percutaneous coronary intervention, 236Sunil V. Rao and E. Magnus Ohman
17 Antithrombotic management in patients with prosthetic valves, 246Eric G. Butchart and Raffaele De Caterina
18 Stroke: thrombolysis and antithrombotic therapy, 272L. Creed Pettigrew and Michael R. Dobbs
19 Atrial fibrillation: current and forthcoming antithrombotic therapies, 285Raffaele De Caterina and Giulia Renda
20 Venous thromboembolism: pathophysiology, diagnosis, and prophylaxis, 306Marco P. Donadini, Walter Ageno, and Alexander G. Turpie
21 Antithrombotic therapy in venous thrombosis and pulmonary embolism, 317Marcello Di Nisio and Harry R. Büller
22 Prevention and treatment of venous and arterial thrombosis in patients with specific conditions: diabetes, hypercoagulable states, pregnancy, and renal insufficiency, 327Meyer Michel Samama, Jacqueline Conard, and Grigoris Gerotziafas
23 Genetics of the response to antithrombotic drugs and the need for monitoring, 357Jean–Philippe Collet, Gilles Montalescot, and Jean–Sébastien Hulot